Nebius falls 10% as company expects increased 2026 capex spend, issues weak outlook
Nebius falls 10% as company expects increased 2026 capex spend, issues weak outlook CNBC
Covered in this story
Analyst targets on Nebius Group
- Rosenblatt Securities: at $221 · target $304 by Oct 2027 · Buy via TIKR.com
- BNP Paribas Exane: at $243 · target $399 by Sep 2027 · Outperform via finance.yahoo.com
- Bank of America: at $278 · target $310 by Aug 2027 · Buy via Yahoo Finance
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $NBIS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nebius Group →Dalsna Finance is currently tracking 51 stories mentioning Nebius Group, the earliest published 30 Jul 2026.
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.